IHE:NYE-iShares U.S. Pharmaceuticals ETF (USD)

ETF | Health |

Last Closing

USD 70.61

Change

+0.53 (+0.76)%

Market Cap

N/A

Volume

0.02M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-30 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

+1.00 (+0.65%)

USD 41.71B
XLV Health Care Select Sector SPDR..

+1.00 (+0.65%)

USD 41.71B
FHLC Fidelity® MSCI Health Care In..

+0.46 (+0.64%)

USD 2.97B
FHLC Fidelity® MSCI Health Care In..

+0.46 (+0.64%)

USD 2.97B
FXH First Trust Health Care AlphaD..

+0.42 (+0.37%)

USD 1.29B
FXH First Trust Health Care AlphaD..

+0.42 (+0.37%)

USD 1.29B
XHE SPDR® S&P Health Care Equipme..

+0.67 (+0.75%)

USD 0.22B
XHE SPDR® S&P Health Care Equipme..

+0.67 (+0.75%)

USD 0.22B
IDNA iShares Genomics Immunology an..

+0.05 (+0.22%)

USD 0.14B
IDNA iShares Genomics Immunology an..

+0.05 (+0.22%)

USD 0.14B

ETFs Containing IHE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 14.26% 88% B+ 68% D+
Dividend Return 1.50% 97% N/A 30% F
Total Return 15.76% 98% N/A 65% D
Trailing 12 Months  
Capital Gain 20.38% 45% F 56% F
Dividend Return 1.81% 97% N/A 26% F
Total Return 22.19% 60% D- 52% F
Trailing 5 Years  
Capital Gain 54.23% 50% F 71% C-
Dividend Return 8.81% 92% A 29% F
Total Return 63.04% 60% D- 69% C-
Average Annual (5 Year Horizon)  
Capital Gain 6.38% N/A N/A 59% D-
Dividend Return 7.74% N/A N/A 56% F
Total Return 1.36% N/A N/A 32% F
Risk Return Profile  
Volatility (Standard Deviation) 11.19% N/A N/A 75% C
Risk Adjusted Return 69.20% N/A N/A 83% B
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike